Durvalumab (Imfinzi, AstraZeneca Inc.)is a monoclonal anti-PD-L1 IgG1 kappa antibody that was approved in, 2018 by the FDA and EMA for treating patients with stage III NSCLC whose tumors cannot be surgically removed and whose cancer has not progressed after chemotherapy and radiation treatment. This evidence concerns the gene CD274 and non-small cell lung carcinoma.